> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises
- URL: https://www.bullished.co/neurocrine-stock-soars-14-adding-2-billion-after-sales-top-1-billion-and-ingrezza-outlook-66b9e482/
- Published: 2026-11-03T15:08:01.000Z
- Updated: 2026-11-03T15:08:01.000Z
- Description: Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.
- Author: Matteo Parrino
- Tags: Markets, NBIX, Industry: Healthcare

[Neurocrine Biosciences](https://www.bullished.co/tag/nbix/), the San Diego drugmaker, saw its shares climb 13.56% to $165.06 in Tuesday trading as of 10:05 a.m. ET, adding about $2 billion in market value. Revenue grew 41% to $1.1 billion. It also raised its 2026 Ingrezza forecast, even as safety questions about its newly acquired Vykat drug lingered.

## Crenessity doubles, Ingrezza adds 17%

Crenessity sales more than doubled to $211 million. Ingrezza reached $801 million, and the 2026 Ingrezza outlook now stands at $2.9 billion to $2.925 billion.

Adjusted third-quarter profit came to $347 million, up from $222 million a year earlier, according to the company's [filing](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/nbix-20261102.htm?ref=bullished.co). The quarter was the company's first with [more than $1 billion](https://www.biospace.com/business/neurocrine-defends-prader-willi-drug-after-another-patient-death?ref=bullished.co) in net product sales.

Neurocrine develops and sells drugs across neurology, psychiatry, endocrinology and immunology. Its approved products treat tardive dyskinesia, Huntington's chorea and classic congenital adrenal hyperplasia, a rare hormone disorder. Ingrezza net product sales were $2.51 billion for 2025, and Crenessity sales were $301.2 million.

## Vykat's safety record and the Soleno deal

The quarter also carried $107 million in sales of Vykat XR. A newly confirmed patient death brought the reported toll to eight, [BioSpace reported](https://www.biospace.com/business/neurocrine-defends-prader-willi-drug-after-another-patient-death?ref=bullished.co).

Neurocrine bought Vykat through its $2.9 billion acquisition of Soleno Therapeutics in April, so the drug's safety record bears directly on what that deal delivers. The company plans a new study in 2027 on dosing and safety in Prader-Willi patients with complex health issues.

## A rally against a lagging year

The stock was on pace for its biggest one-day gain in at least 275 trading sessions, the last comparable one coming on Sept. 30, 2025.

As of Monday's close, the shares were up about 3% year to date, trailing the S&P 500's gain of about 10%. They sat 22% below their highest close of the past year, set on July 30.

Neurocrine's 2027 study of Vykat dosing and safety in Prader-Willi patients with complex health issues is the next marker for the drug.

### Sources

- [Neurocrine: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/neurocrine-q3-earnings-snapshot-043145015.html?ref=bullished.co) — Associated Press
- [Neurocrine defends Prader-Willi drug after another patient death - BioSpace](https://www.biospace.com/business/neurocrine-defends-prader-willi-drug-after-another-patient-death?ref=bullished.co) — biospace.com
- [Neurocrine Biosciences Non-GAAP EPS of $3.29 beats by $0.54, revenue of $1.12B beats by $80M (NBIX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4662929-neurocrine-biosciences-non-gaap-eps-of-329-beats-by-054-revenue-of-112b-beats-by-80m?ref=bullished.co) — seekingalpha.com
- [Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say](https://finance.yahoo.com/markets/stocks/articles/neurocrine-nbix-reports-q3-earnings-223001105.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Neurocrine: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/neurocrine-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [The company's filing (Neurocrine Biosciences)](https://www.sec.gov/Archives/edgar/data/0000914475/000091447526000053/nbix-20261102.htm?ref=bullished.co) — SEC filing
- [Neurocrine Biosciences — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000054/nbix-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Neurocrine Biosciences

- [Neurocrine Says FDA Flagged Fluid Retention As A Potential Safety Signal For Its Newly Bought VYKAT XR](https://www.bullished.co/neurocrine-says-fda-flagged-fluid-retention-as-a-potential-safety-signal-for-its-newly-f0dab2f2/)
- [Neurocrine's Product Sales Top $1 Billion In A Quarter For The First Time, And Ingrezza Outlook Rises](https://www.bullished.co/neurocrines-product-sales-top-1-billion-in-a-quarter-for-the-first-time-and-ingrezza-27d7732d/)
- [Vanguard Portfolio Management Reports 5% Passive Stake In Neurocrine Biosciences](https://www.bullished.co/vanguard-portfolio-management-reports-5-passive-stake-in-neurocrine-biosciences-ef0bebad/)

[All Neurocrine Biosciences (NBIX) coverage →](https://www.bullished.co/tag/nbix/)